Q3 2025 Pharma Services Update
Subsector Spotlight: Pharmaceutical Commercialization
M&A activity within the outsourced pharmaceutical commercialization sector remained robust this quarter, underpinned by ongoing strategic consolidation and reinforced investor confidence following a series of successful exits in 2025.
Both strategic acquirers and investors continue to prioritize and assign premium valuations to commercialization partners with demonstrated analytical capabilities and realworld evidence (“RWE”) expertise, recognizing their critical role in enhancing commercial strategies. This trend was further exemplified by Minds + Assembly’s acquisition of Stratevi, which expands its analytics and evidence development capabilities to support insights. Provident anticipates sustained M&A momentum in H1 2026, with several comparable transactions expected to follow.
To print and download the full Pharma Services Update report, please click below…
